Last reviewed · How we verify
Magnetic resonance imaging
Approved treatments
- Gastromark · Amag Pharms Inc
- Optimark · Liebel-Flarsheim
- Gadoterate · Loyola University
- Gadovist · Vanderbilt University Medical Center
- Gadavist · Brigham and Women's Hospital
- Omniscan · GE HealthCare
- Dotarem · Guerbet
Gadoterate enhances MRI image brightness by shortening T1 and T2 relaxation times in tissues. - Gadavist · Bayer
Gadavist works by binding to gadolinium ions, which then accumulate in body tissues and enhance MRI signal. - Omniscan · GE Healthcare
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Magnetic resonance imaging patent landscape — cliff calendar, originator estates, attackable patents
- Magnetic resonance imaging treatment landscape brief
- Magnetic resonance imaging treatment updates RSS
Frequently asked questions about Magnetic resonance imaging
What drugs treat Magnetic resonance imaging?
Tracked treatments include Gastromark, Optimark, Gadoterate, Gadovist, Gadavist, Omniscan, Dotarem.
What is the treatment for Magnetic resonance imaging?
Standard treatment for Magnetic resonance imaging includes Gastromark, Optimark, Gadoterate, Gadovist, Gadavist. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Magnetic resonance imaging patent cliff · Magnetic resonance imaging CI report
- Treatment: Gastromark · Amag Pharms Inc
- Treatment: Optimark · Liebel-Flarsheim
- Treatment: Gadoterate · Loyola University
- Treatment: Gadovist · Vanderbilt University Medical Center
- Treatment: Gadavist · Brigham and Women's Hospital
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing